Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735 · View on ClinicalTrials.gov ↗

Study Summary

Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.

Interventions

  • DRUG Enoxaparin
  • DEVICE ActiveCare CECT device

Study Locations (9)

California

  • Scripps Clinic — La Jolla
  • Empire Orthopedic Center — Loma Linda
  • Cedars-Sinai Medical Center — Los Angeles

Indiana

  • The center for hip and knee surgery — Mooresville

Maryland

  • Center for Joint Preservation and Replacement, Sinai Hospital of Baltimore — Baltimore

Minnesota

  • Mayo Clinic — Rochester

New York

  • Hospital for Special Surgery — New York

Ohio

  • Cleveland Clinic — Cleveland

Oregon

  • The Center Orthopedic & Neurosurgical Care &Research — Bend

Trial Details

FieldValue
Enrollment Target 411 participants
Start Date 2006-06
Est. Completion 2008-12
Phase NA

Sponsor

Medical Compression Systems

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00358735

The ClinicalTrials.gov registry entry for NCT00358735 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical Compression Systems, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Bleeding appearing as the primary indexed condition, and to 2 interventions — of which Enoxaparin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00358735 reports 9 study locations spanning 7 distinct geographic areas — top geographies include California, Indiana, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00358735 about?

NCT00358735 is a clinical study titled "Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)". Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.

What is the current status of trial NCT00358735?

This trial is currently completed. It is a NA study. The enrollment target is 411 participants. The study started on 2006-06. Estimated completion is 2008-12.

What conditions does trial NCT00358735 study?

This clinical trial studies the following conditions: Bleeding, Pulmonary Embolism (PE), Deep Vein Thrombosis of Lower Limb. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00358735?

The interventions under investigation include: Enoxaparin (DRUG), ActiveCare CECT device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00358735?

This trial is sponsored by Medical Compression Systems, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00358735 being conducted?

This trial has 9 study locations across California, Indiana, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial